Conforti, Fabio

Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis

Conforti, F., Pala, L., Bagnardi, V., De Pas, T., Martinetti, M., Viale, G., Gelber, R. D., & Goldhirsch, A. (2018) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersSex and Gender in Healthcare

Cited by 973

Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis

Conforti, F., Pala, L., Bagnardi, V., Viale, G., De Pas, T., Pagan, E., Pennacchioli, E., Cocorocchio, E., Ferrucci, P. F., De Marinis, F., et al. (2019) · JNCI: Journal of the National Cancer Institute

Cancer Immunotherapy and BiomarkersLung Cancer Research Studies

Cited by 262

Dasatinib sensitises KRAS -mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity

Rao, G., Kim, I.-K., Conforti, F., Liu, J., Zhang, Y.-W., & Giaccone, G. (2018) · European Journal of Cancer

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 34

Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1 oncogenic functions in AML

Nicosia, L., Boffo, F. L., Ceccacci, E., Conforti, F., Pallavicini, I., Bedin, F., Ravasio, R., Massignani, E., Somervaille, T. C. P., Minucci, S., et al. (2022) · Oncogene

Acute Myeloid Leukemia ResearchEpigenetics and DNA Methylation

Cited by 31